Warning Letter Record: Shimoga Chemicals (2026-07-13) — CGMP/Active Pharmaceutical Ingredient (API)/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated
TL;DR
In short: The FDA's Center for Drug Evaluation and Research (CDER) issued Warning Letter 320-26-101 on July 13, 2026, to Shimoga Chemicals (FEI 3033881432, Sangli, India) following a January 19–23, 2026 inspection, citing significant CGMP deviations for clomiphene citrate USP APIs distributed to the U.S. market. The letter documents data integrity failures (undocumented HPLC injections, unreported out-of-specification results, inadequate electronic data review), inadequate sampling procedures (unspecified quantities, locations, and timing), and unverified analytical test methods, rendering distributed batches adulterated under 21 U.S.C. 351(a)(2)(B). The FDA deemed the facility's February 10, 2026 response insufficient and requested comprehensive independent laboratory assessment, detailed remediation plans, and retrospective review of all invalidated out-of-specification results for U.S. APIs from the prior three years.
Argus analysis
# FDA Warning Letter Analysis: Shimoga Chemicals
**Company and Findings**
Shimoga Chemicals, a drug manufacturer located in Maharashtra, India (FEI 3033881432), received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) on July 13, 2026, following an inspection conducted January 19–23, 2026. The FDA identified significant deviations from Current Good Manufacturing Practice (CGMP) standards in the production of clomiphene citrate USP, an active pharmaceutical ingredient intended for pharmacy compounding and U.S. distribution. The FDA determined that the company's APIs are adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act.
**Specific Violations**
The warning letter cites multiple failures across three primary areas. First, the company failed to ensure scientifically sound specifications and testing procedures under 21 CFR Part 211, specifically regarding data integrity. The FDA documented unreported HPLC injections showing out-of-specification assay results that were not recorded in batch records, yet batches were released to the U.S. market anyway. Second, the company lacked adequate sampling procedures and controls—batch records failed to specify sample quantities, locations, or methodology. Third, the company did not perform method verification studies for identification, related substances, residual solvents, or assay testing, meaning test results cannot reliably confirm product quality.
**Next Steps and Industry Watch Points**
Shimoga Chemicals must submit a comprehensive independent laboratory assessment, a retrospective review of all out-of-specification results from the past three years, and detailed remediation plans addressing data integrity, process validation, and sampling operations. Compliance peers should monitor whether the company engages qualified third-party reviewers and whether the FDA issues a close-out letter within 12 months. Import alerts affecting this manufacturer's products may follow if corrective actions prove insufficient.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Shimoga Chemicals MARCS-CMS 727904 — July 13, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Reference #: 320-26-101 Product: Drugs Recipient: Recipient Name Mr. C. Srinivas Rao Recipient Title Partner Shimoga Chemicals W57A, MIDC, Kupwad Sangli 416436 Maharashtra India Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-101 July 13, 2026 Dear Mr. Rao: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Shimoga Chemicals, FEI 3033881432, at W57A, MIDC, Kupwad, Sangli, Maharashtra, 416436, India, from January 19 to 23, 2026. This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your February 10, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. During our inspection, our investigators observed specific deviations including, but not limited to, the following. 1. Failure to ensure that all specifications, sampling plans, test procedures are scientifically sound and appropriate to ensure that your API conform to established standards of quality and purity. Your firm manufactures the API, clomiphene citrate USP for U.S. distribution, intended for pharmacy compounding. Data Integrity Concerns Your firm failed to establish adequate controls over analytical testing data. Multiple instances of unreported sample injections for related substances and assay testing by high performance liquid chromatography (HPLC) were not documented in laboratory batch records. For example, clomiphene citrate USP batch CC/005/24-25 had an unreported injection with an out-of-specification (OOS) assay result of (b)(4) % (specification: (b)(4) %); however, the reported injection result of (b)(4) % was documented in the batch record. Additionally, because your firm lacked procedures for electronic data review and your quality unit (QU) did not review the electronic data, this batch was subsequently released and distributed to the U.S. market. Without reliable analytical data, there is no assurance that distributed API batches meet identity, strength, quality, or purity specifications. Your response is inadequate. In your response, you acknowledge undocumented trial injections, unreported analytical data, discarded printouts, and inadequate review of electronic laboratory records. You also commit to a retrospective review of all U.S. batches, including electronic data and documentation. You further mention hiring a third-party data integrity expert. However, your response does not descr…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Shimoga Chemicals had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Shimoga Chemicals as of 2026-07-21. Argus ingests new FDA enforcement records daily.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Warning Letter Record: Shimoga Chemicals (2026-07-13) — CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-shimoga-chemicals-2026-07-13-cgmp
"Warning Letter Record: Shimoga Chemicals (2026-07-13) — CGMP/Active Pharmaceutical Ingredient (API)/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-shimoga-chemicals-2026-07-13-cgmp.
Argus HQ Research. "Warning Letter Record: Shimoga Chemicals (2026-07-13) — CGMP/Active Pharmaceutical Ingredient (API)/Adulterated." Digital Empire Holdings LLC. Accessed July 22, 2026. https://argushq.ai/fda/warning-letter/fda-wl-shimoga-chemicals-2026-07-13-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_shimoga_chemicals_2026_07_13_cgmp_2026,
title = {Warning Letter Record: Shimoga Chemicals (2026-07-13) — CGMP/Active Pharmaceutical Ingredient (API)/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-shimoga-chemicals-2026-07-13-cgmp},
note = {Accessed: July 22, 2026}
}